NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC Interim response and peripheral immunomodulation data from its Phase 2 clinical trial of IT LSAM-PTX in stage 3/4 lung ca ...
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer FORT WORTH (November 20, 2023) — NanOlogy LLC, a clinical-stage oncology ...
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting FORT WORTH (October 23, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced to ...
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer Research article published in Pancreas ...
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer FORT WORTH (September 12, 2023) — NanOlogy LLC, a clinica ...
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs FORT WORTH, Texas--NanOlogy LLC, a clinical-stage oncolog ...
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer Covers intratumoral delivery of certain LSAM investigational ...